PRL-3 has also been proposed as a biomarker for advanced malignancy in gastric cancer, ovarian cancer, colorectal carcinoma etc. and implicates poor clinical outcome [5], [6]. This evidence concerns the gene PTP4A3 and colorectal carcinoma.